{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:52:02Z","timestamp":1772754722477,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi-Genzyme, Research Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fabry disease is an X-linked deficiency of the lysosomal hydrolase alpha-galactosidase A (alpha-Gal). This results in an accumulation of globotriaosylceramide (GL-3\/Gb3) in a variety of cells with subsequent functional impairment. The continuous progress of FD often leads to decreased quality of life and premature death caused by multi-organic complications. The overall aim of our study was to determine the amount of circulating miRNAs in Fabry patients and to test whether ERT would alter the level of individual circulating miRNAs. We used miRNA sequencing by the HTG EdgeSeq System to identify the circulating miRNA pool from Fabry patients with and without enzyme replacement therapy (n\u2009=\u20096). In total, 296 miRNAs in serum of patients were identified. Among them 9 miRNAs were further evaluated in extra serum samples (n\u2009=\u200931) using real-time qPCR and 6 of them showed significant differential expression. The resulting miRNA pattern may help to better understand mechanisms involved in the beneficial effects of ERT and these new miRNA markers could help to estimate the efficacy of ERT or to identify Fabry patients with specific need for ERT.<\/jats:p>","DOI":"10.1038\/s41598-019-51805-6","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T12:20:45Z","timestamp":1572006045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Circulating microRNAs in Fabry Disease"],"prefix":"10.1038","volume":"9","author":[{"given":"Ke","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongchao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine","family":"Hoepfner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Santer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Pfanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Thum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2560-4068","authenticated-orcid":false,"given":"Peter","family":"Nordbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-1511","authenticated-orcid":false,"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"key":"51805_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1146\/annurev-med-090910-085119","volume":"62","author":"F Weidemann","year":"2011","unstructured":"Weidemann, F., Niemann, M., Warnock, D. G., Ertl, G. & Wanner, C. The Fabry cardiomyopathy: models for the cardiologist. Annu. Rev. Med. 62, 59\u201367 (2011).","journal-title":"Annu. Rev. Med."},{"key":"51805_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/08035250500275022","volume":"95","author":"U Ramaswami","year":"2006","unstructured":"Ramaswami, U. et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 95, 86\u201392 (2006).","journal-title":"Acta Paediatr."},{"key":"51805_CR3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot, K. D., Holmes, A. & Miners, A. H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet. 38, 750\u2013760 (2001).","journal-title":"J. Med. Genet."},{"key":"51805_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot, K. D., Holmes, A. & Miners, A. H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet. 38, 769\u2013775 (2001).","journal-title":"J. Med. Genet."},{"key":"51805_CR5","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann, R. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285, 2743\u20132749 (2001).","journal-title":"JAMA"},{"key":"51805_CR6","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta, A. et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet 374, 1986\u20131996 (2009).","journal-title":"Lancet"},{"key":"51805_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann, F. et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119, 524\u2013529 (2009).","journal-title":"Circulation"},{"key":"51805_CR8","unstructured":"Hughes, D. A. et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J. Med. Genet. (2016)."},{"key":"51805_CR9","doi-asserted-by":"publisher","unstructured":"Reisin, R., Perrin, A. & Garcia-Pavia, P. Time delays in the diagnosis and treatment of Fabry disease. Int. J. Clin. Pract. 71 https:\/\/doi.org\/10.1111\/ijcp.12914 (2017).","DOI":"10.1111\/ijcp.12914"},{"key":"51805_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/138161282104141204142643","volume":"21","author":"F Weidemann","year":"2015","unstructured":"Weidemann, F., Ertl, G., Wanner, C. & Kramer, J. The Fabry cardiomyopathy - diagnostic approach and current treatment. Curr. Pharm. Des. 21, 473\u2013478 (2015).","journal-title":"Curr. Pharm. Des."},{"key":"51805_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","volume":"121","author":"A Nowak","year":"2017","unstructured":"Nowak, A., Mechtler, T., Kasper, D. C. & Desnick, R. J. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease. Mol. Genet. Metab. 121, 320\u2013324 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"51805_CR12","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1073\/pnas.0611315104","volume":"104","author":"DF Moore","year":"2007","unstructured":"Moore, D. F. et al. Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. Proc. Natl. Acad. Sci. USA 104, 2873\u20132878 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51805_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.111.039008","volume":"124","author":"J Fiedler","year":"2011","unstructured":"Fiedler, J. et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124, 720\u2013730 (2011).","journal-title":"Circulation"},{"key":"51805_CR14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nature07511","volume":"456","author":"T Thum","year":"2008","unstructured":"Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980\u2013984 (2008).","journal-title":"Nature"},{"key":"51805_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1161\/CIRCRESAHA.116.308434","volume":"120","author":"J Viereck","year":"2017","unstructured":"Viereck, J. & Thum, T. Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury. Circ. Res. 120, 381\u2013399 (2017).","journal-title":"Circ. Res."},{"key":"51805_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten, M. et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J. Rare Dis. 10, 36-015-0253-6 (2015).","journal-title":"Orphanet J. Rare Dis."},{"key":"51805_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/ejhf.116","volume":"16","author":"AC Morley-Smith","year":"2014","unstructured":"Morley-Smith, A. C. et al. Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device. Eur. J. Heart Fail. 16, 871\u2013879 (2014).","journal-title":"Eur. J. Heart Fail."},{"key":"51805_CR18","doi-asserted-by":"crossref","unstructured":"Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106-2010-11-10-r106. Epub 2010 Oct 27 (2010).","DOI":"10.1186\/gb-2010-11-10-r106"},{"key":"51805_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/bib\/bbt086","volume":"16","author":"F Seyednasrollah","year":"2015","unstructured":"Seyednasrollah, F., Laiho, A. & Elo, L. L. Comparison of software packages for detecting differential expression in RNA-seq studies. Brief Bioinform 16, 59\u201370 (2015).","journal-title":"Brief Bioinform"},{"key":"51805_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"51805_CR21","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu, T. & Vilo, J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 43, W566\u201370 (2015).","journal-title":"Nucleic Acids Res."},{"key":"51805_CR22","first-page":"506","volume":"8","author":"F Yang","year":"2016","unstructured":"Yang, F., Xu, Z., Duan, S. & Luo, M. MicroRNA-541 promotes the proliferation of vascular smooth muscle cells by targeting IRF7. Am. J. Transl. Res. 8, 506\u2013515 (2016).","journal-title":"Am. J. Transl. Res."},{"key":"51805_CR23","doi-asserted-by":"publisher","first-page":"121ra18","DOI":"10.1126\/scitranslmed.3003205","volume":"4","author":"BN Chau","year":"2012","unstructured":"Chau, B. N. et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med. 4, 121ra18 (2012).","journal-title":"Sci. Transl. Med."},{"key":"51805_CR24","doi-asserted-by":"publisher","first-page":"10765","DOI":"10.1073\/pnas.1301693110","volume":"110","author":"V Patel","year":"2013","unstructured":"Patel, V. et al. miR-17~92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc. Natl. Acad. Sci. USA 110, 10765\u201310770 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51805_CR25","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1681\/ASN.2014030248","volume":"26","author":"XY Zhu","year":"2015","unstructured":"Zhu, X. Y. et al. Renal Vein Levels of MicroRNA-26a Are Lower in the Poststenotic Kidney. J. Am. Soc. Nephrol. 26, 1378\u20131388 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"51805_CR26","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1136\/jmg.40.4.e38","volume":"40","author":"N Guffon","year":"2003","unstructured":"Guffon, N. Clinical presentation in female patients with Fabry disease. J. Med. Genet. 40, e38 (2003).","journal-title":"J. Med. Genet."},{"key":"51805_CR27","doi-asserted-by":"publisher","first-page":"W460","DOI":"10.1093\/nar\/gkv403","volume":"43","author":"IS Vlachos","year":"2015","unstructured":"Vlachos, I. S. et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 43, W460\u20136 (2015).","journal-title":"Nucleic Acids Res."},{"key":"51805_CR28","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","volume":"62","author":"MJ Hilz","year":"2004","unstructured":"Hilz, M. J., Brys, M., Marthol, H., Stemper, B. & Dutsch, M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 62, 1066\u20131072 (2004).","journal-title":"Neurology"},{"key":"51805_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann, R., Ries, M., Timmons, M., Flaherty, J. T. & Brady, R. O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant. 21, 345\u2013354 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"51805_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","volume":"30","author":"MH Lee","year":"2012","unstructured":"Lee, M. H., Choi, E. N., Jeon, Y. J. & Jung, S. C. Possible role of transforming growth factor-beta1 and vascular endothelial growth factor in Fabry disease nephropathy. Int. J. Mol. Med. 30, 1275\u20131280 (2012).","journal-title":"Int. J. Mol. Med."},{"key":"51805_CR31","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1093\/ndt\/gfr485","volume":"26","author":"CS Neal","year":"2011","unstructured":"Neal, C. S. et al. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol. Dial. Transplant. 26, 3794\u20133802 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"51805_CR32","first-page":"4980942","volume":"2019","author":"S Jaurretche","year":"2019","unstructured":"Jaurretche, S., Perez, G. R. & Venera, G. High Lyso-Gb3 Plasma Levels Associated with Decreased miR-29 and miR-200 Urinary Excretion in Young Non-Albuminuric Male Patient with Classic Fabry Disease. Case Rep. Nephrol. 2019, 4980942 (2019).","journal-title":"Case Rep. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51805-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51805-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51805-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T14:55:59Z","timestamp":1671288959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51805-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["51805"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-51805-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"5 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was partly sponsored by Sanofi\/Genzyme. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15277"}}